Trial Profile
A Phase 1b/2a, Open Label Study to Evaluate Anti-tumor Efficacy and Safety of rhIL-7-hyFc (NT-I7) in Combination With Anti-PD-L1 (Atezolizumab) in Patients With Anti-PD-1/PD-L1 naïve or Relapsed/Refractory High-risk Skin Cancers
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 26 Feb 2024
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Efineptakin alfa (Primary)
- Indications Malignant melanoma; Merkel cell carcinoma; Skin cancer; Squamous cell cancer
- Focus Adverse reactions
- Sponsors NeoImmuneTech
- 20 Feb 2024 Status changed from active, no longer recruiting to discontinued.
- 14 Feb 2023 Status changed from recruiting to active, no longer recruiting.
- 07 Jun 2022 Results (n=16; as of 14 Jan 2022) reporting efficacy and safety data from Phase 1b portion of this trial presented at the 58th Annual Meeting of the American Society of Clinical Oncology